Edwards Lifesciences Co. (NYSE:EW) CFO Sells $622,050.00 in Stock

Edwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem sold 7,250 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $85.80, for a total value of $622,050.00. Following the transaction, the chief financial officer now owns 19,074 shares in the company, valued at approximately $1,636,549.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $85.06 on Friday. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The company has a market cap of $51.26 billion, a price-to-earnings ratio of 36.66, a PEG ratio of 3.56 and a beta of 1.10. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The business’s 50 day moving average price is $90.13 and its 200 day moving average price is $79.23.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. On average, research analysts predict that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Hedge Funds Weigh In On Edwards Lifesciences

A number of institutional investors have recently added to or reduced their stakes in EW. DSM Capital Partners LLC purchased a new stake in Edwards Lifesciences in the fourth quarter valued at $28,000. Turtle Creek Wealth Advisors LLC purchased a new stake in Edwards Lifesciences in the fourth quarter valued at $34,000. Riverview Trust Co purchased a new stake in Edwards Lifesciences in the first quarter valued at $34,000. Pingora Partners LLC purchased a new stake in Edwards Lifesciences in the fourth quarter valued at $38,000. Finally, Operose Advisors LLC raised its position in Edwards Lifesciences by 247.0% in the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 452 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on EW shares. Mizuho increased their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Oppenheimer increased their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, March 18th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Wells Fargo & Company raised their target price on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research report on Friday, April 26th. Finally, Evercore ISI decreased their target price on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $92.71.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.